Apyx Medical (NASDAQ:APYX) Upgraded at BTIG Research

BTIG Research upgraded shares of Apyx Medical (NASDAQ:APYX) from a neutral rating to a buy rating in a research report sent to investors on Wednesday morning, MarketBeat Ratings reports. The firm currently has $6.00 target price on the stock.

A number of other research analysts also recently commented on the company. Citizens Jmp upgraded Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 price objective on the stock in a report on Wednesday, November 12th. Roth Mkm initiated coverage on Apyx Medical in a research note on Monday, December 15th. They set a “buy” rating and a $6.00 target price for the company. Zacks Research raised Apyx Medical to a “hold” rating in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a research note on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Apyx Medical to a “hold” rating in a research report on Saturday, November 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.50.

Apyx Medical Price Performance

Shares of APYX opened at $3.63 on Wednesday. The firm has a market capitalization of $151.84 million, a price-to-earnings ratio of -13.44 and a beta of 1.61. The firm’s fifty day simple moving average is $3.75 and its 200-day simple moving average is $3.33. Apyx Medical has a twelve month low of $0.76 and a twelve month high of $4.50. The company has a current ratio of 5.00, a quick ratio of 3.61 and a debt-to-equity ratio of 2.35.

Apyx Medical (NASDAQ:APYX) last issued its earnings results on Tuesday, March 10th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. The firm had revenue of $19.16 million during the quarter, compared to the consensus estimate of $19.12 million. Apyx Medical had a negative net margin of 21.22% and a negative return on equity of 114.95%. Equities analysts forecast that Apyx Medical will post -0.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in APYX. Millennium Management LLC acquired a new position in Apyx Medical during the fourth quarter worth approximately $324,000. 683 Capital Management LLC acquired a new stake in shares of Apyx Medical in the fourth quarter valued at approximately $436,000. ExodusPoint Capital Management LP purchased a new position in shares of Apyx Medical during the fourth quarter worth approximately $305,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Apyx Medical during the fourth quarter worth approximately $111,000. Finally, Nantahala Capital Management LLC increased its holdings in shares of Apyx Medical by 19.1% in the 4th quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company’s stock valued at $13,909,000 after acquiring an additional 636,043 shares during the period. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.